The most common adverse event was injection site reactions that have been predominantly slight and typically resolved within days. There were ‘no flu-like’ symptoms, no abnormalities in renal function, no clinically meaningful changes in other laboratory values reported as adverse events. Liver enzyme elevations had been noted as adverse occasions in two patients but are not being thought to be clinically meaningful in these situations. The positive safety profile demonstrated to date suggests the drug may be tolerated at higher dosage levels than 400 mg weekly. Preparation for Phase III Development As previously reported, THE BUSINESS plans to conduct a small study at a higher dosage than 400 mg weekly for potential make use of in a Stage III medical trial.The scholarly studies are proceeding on schedule. Related StoriesBlocking calcium-signaling pathway could inhibit Ebola virus and various other sources of deadly infectionsFour microRNAs may actually play critical functions in managing cholesterol, triglyceride metabolismNew vaccine is apparently far better in reducing 'awful' LDL cholesterol’This decision highlights the opportunity for broader treatment in lots of higher at-risk populations,’ stated Eugene Sunlight, M.D., vice president, Global Pharmaceutical Clinical Development, Abbott. ‘We’re looking forward to discovering the potential of a combination treatment to address the needs of patients.’ ‘AstraZeneca is focused on continually investigate brand-new treatment options for individuals at risk for coronary disease,’ stated James Blasetto M.D., Vice President, Strategic Development, AstraZeneca.